1
|
Ruiz M, Khairallah M, Dingar D, Vaniotis G, Khairallah RJ, Lauzier B, Thibault S, Trépanier J, Shi Y, Douillette A, Hussein B, Nawaito SA, Sahadevan P, Nguyen A, Sahmi F, Gillis MA, Sirois MG, Gaestel M, Stanley WC, Fiset C, Tardif JC, Allen BG. MK2-Deficient Mice Are Bradycardic and Display Delayed Hypertrophic Remodeling in Response to a Chronic Increase in Afterload. J Am Heart Assoc 2021; 10:e017791. [PMID: 33533257 PMCID: PMC7955338 DOI: 10.1161/jaha.120.017791] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
Background Mitogen‐activated protein kinase–activated protein kinase‐2 (MK2) is a protein serine/threonine kinase activated by p38α/β. Herein, we examine the cardiac phenotype of pan MK2‐null (MK2−/−) mice. Methods and Results Survival curves for male MK2+/+ and MK2−/− mice did not differ (Mantel‐Cox test, P=0.580). At 12 weeks of age, MK2−/− mice exhibited normal systolic function along with signs of possible early diastolic dysfunction; however, aging was not associated with an abnormal reduction in diastolic function. Both R‐R interval and P‐R segment durations were prolonged in MK2‐deficient mice. However, heart rates normalized when isolated hearts were perfused ex vivo in working mode. Ca2+ transients evoked by field stimulation or caffeine were similar in ventricular myocytes from MK2+/+ and MK2−/− mice. MK2−/− mice had lower body temperature and an age‐dependent reduction in body weight. mRNA levels of key metabolic genes, including Ppargc1a, Acadm, Lipe, and Ucp3, were increased in hearts from MK2−/− mice. For equivalent respiration rates, mitochondria from MK2−/− hearts showed a significant decrease in Ca2+ sensitivity to mitochondrial permeability transition pore opening. Eight weeks of pressure overload increased left ventricular mass in MK2+/+ and MK2−/− mice; however, after 2 weeks the increase was significant in MK2+/+ but not MK2−/− mice. Finally, the pressure overload–induced decrease in systolic function was attenuated in MK2−/− mice 2 weeks, but not 8 weeks, after constriction of the transverse aorta. Conclusions Collectively, these results implicate MK2 in (1) autonomic regulation of heart rate, (2) cardiac mitochondrial function, and (3) the early stages of myocardial remodeling in response to chronic pressure overload.
Collapse
Affiliation(s)
- Matthieu Ruiz
- Department of Medicine Université de Montréal Québec Canada.,Montreal Heart Institute Montréal Québec Canada
| | - Maya Khairallah
- Department of Biochemistry and Molecular Medicine Université de Montréal Québec Canada.,Montreal Heart Institute Montréal Québec Canada
| | - Dharmendra Dingar
- Department of Biochemistry and Molecular Medicine Université de Montréal Québec Canada.,Montreal Heart Institute Montréal Québec Canada
| | - George Vaniotis
- Department of Biochemistry and Molecular Medicine Université de Montréal Québec Canada.,Montreal Heart Institute Montréal Québec Canada
| | | | | | - Simon Thibault
- Faculté de Pharmacie Université de Montréal Québec Canada.,Montreal Heart Institute Montréal Québec Canada
| | - Joëlle Trépanier
- Department of Biochemistry and Molecular Medicine Université de Montréal Québec Canada.,Montreal Heart Institute Montréal Québec Canada
| | - Yanfen Shi
- Montreal Heart Institute Montréal Québec Canada
| | | | | | - Sherin Ali Nawaito
- Department of Pharmacology and Physiology Université de Montréal Québec Canada.,Montreal Heart Institute Montréal Québec Canada.,Department of Physiology Faculty of Medicine Suez Canal University Ismailia Egypt
| | - Pramod Sahadevan
- Department of Biochemistry and Molecular Medicine Université de Montréal Québec Canada.,Montreal Heart Institute Montréal Québec Canada
| | - Albert Nguyen
- Department of Pharmacology and Physiology Université de Montréal Québec Canada.,Montreal Heart Institute Montréal Québec Canada
| | | | | | - Martin G Sirois
- Department of Pharmacology and Physiology Université de Montréal Québec Canada.,Montreal Heart Institute Montréal Québec Canada
| | - Matthias Gaestel
- Institute of Cell BiochemistryHannover Medical School Hannover Germany
| | | | - Céline Fiset
- Faculté de Pharmacie Université de Montréal Québec Canada.,Montreal Heart Institute Montréal Québec Canada
| | - Jean-Claude Tardif
- Department of Medicine Université de Montréal Québec Canada.,Montreal Heart Institute Montréal Québec Canada
| | - Bruce G Allen
- Department of Medicine Université de Montréal Québec Canada.,Department of Biochemistry and Molecular Medicine Université de Montréal Québec Canada.,Department of Pharmacology and Physiology Université de Montréal Québec Canada.,Montreal Heart Institute Montréal Québec Canada
| |
Collapse
|
2
|
Tu WB, Shiah YJ, Lourenco C, Mullen PJ, Dingar D, Redel C, Tamachi A, Ba-Alawi W, Aman A, Al-Awar R, Cescon DW, Haibe-Kains B, Arrowsmith CH, Raught B, Boutros PC, Penn LZ. MYC Interacts with the G9a Histone Methyltransferase to Drive Transcriptional Repression and Tumorigenesis. Cancer Cell 2018; 34:579-595.e8. [PMID: 30300580 DOI: 10.1016/j.ccell.2018.09.001] [Citation(s) in RCA: 74] [Impact Index Per Article: 12.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/21/2017] [Revised: 06/30/2018] [Accepted: 09/04/2018] [Indexed: 12/22/2022]
Abstract
MYC is an oncogenic driver that regulates transcriptional activation and repression. Surprisingly, mechanisms by which MYC promotes malignant transformation remain unclear. We demonstrate that MYC interacts with the G9a H3K9-methyltransferase complex to control transcriptional repression. Inhibiting G9a hinders MYC chromatin binding at MYC-repressed genes and de-represses gene expression. By identifying the MYC box II region as essential for MYC-G9a interaction, a long-standing missing link between MYC transformation and gene repression is unveiled. Across breast cancer cell lines, the anti-proliferative response to G9a pharmacological inhibition correlates with MYC sensitivity and gene signatures. Consistently, genetically depleting G9a in vivo suppresses MYC-dependent tumor growth. These findings unveil G9a as an epigenetic regulator of MYC transcriptional repression and a therapeutic vulnerability in MYC-driven cancers.
Collapse
Affiliation(s)
- William B Tu
- Princess Margaret Cancer Centre, Toronto, ON M5G1L7, Canada; Department of Medical Biophysics, University of Toronto, Toronto, ON M5G1L7, Canada
| | - Yu-Jia Shiah
- Informatics and Biocomputing Program, Ontario Institute for Cancer Research, Toronto, ON M5G0A3, Canada
| | - Corey Lourenco
- Princess Margaret Cancer Centre, Toronto, ON M5G1L7, Canada; Department of Medical Biophysics, University of Toronto, Toronto, ON M5G1L7, Canada
| | - Peter J Mullen
- Princess Margaret Cancer Centre, Toronto, ON M5G1L7, Canada
| | | | - Cornelia Redel
- Princess Margaret Cancer Centre, Toronto, ON M5G1L7, Canada; Department of Medical Biophysics, University of Toronto, Toronto, ON M5G1L7, Canada
| | - Aaliya Tamachi
- Princess Margaret Cancer Centre, Toronto, ON M5G1L7, Canada
| | - Wail Ba-Alawi
- Princess Margaret Cancer Centre, Toronto, ON M5G1L7, Canada; Department of Medical Biophysics, University of Toronto, Toronto, ON M5G1L7, Canada
| | - Ahmed Aman
- Drug Discovery Program, Ontario Institute for Cancer Research, Toronto, ON M5G0A3, Canada
| | - Rima Al-Awar
- Drug Discovery Program, Ontario Institute for Cancer Research, Toronto, ON M5G0A3, Canada; Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON M5S1A8, Canada
| | - David W Cescon
- Princess Margaret Cancer Centre, Toronto, ON M5G1L7, Canada; Division of Medical Oncology and Hematology, Department of Medicine, University of Toronto, Toronto, ON M5G2C4, Canada
| | - Benjamin Haibe-Kains
- Princess Margaret Cancer Centre, Toronto, ON M5G1L7, Canada; Department of Medical Biophysics, University of Toronto, Toronto, ON M5G1L7, Canada
| | - Cheryl H Arrowsmith
- Princess Margaret Cancer Centre, Toronto, ON M5G1L7, Canada; Department of Medical Biophysics, University of Toronto, Toronto, ON M5G1L7, Canada; Structural Genomics Consortium, Toronto, ON M5G1L7, Canada
| | - Brian Raught
- Princess Margaret Cancer Centre, Toronto, ON M5G1L7, Canada; Department of Medical Biophysics, University of Toronto, Toronto, ON M5G1L7, Canada
| | - Paul C Boutros
- Department of Medical Biophysics, University of Toronto, Toronto, ON M5G1L7, Canada; Informatics and Biocomputing Program, Ontario Institute for Cancer Research, Toronto, ON M5G0A3, Canada; Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON M5S1A8, Canada
| | - Linda Z Penn
- Princess Margaret Cancer Centre, Toronto, ON M5G1L7, Canada; Department of Medical Biophysics, University of Toronto, Toronto, ON M5G1L7, Canada.
| |
Collapse
|
3
|
Dingar D, Tu WB, Resetca D, Lourenco C, Tamachi A, De Melo J, Houlahan KE, Kalkat M, Chan PK, Boutros PC, Raught B, Penn LZ. MYC dephosphorylation by the PP1/PNUTS phosphatase complex regulates chromatin binding and protein stability. Nat Commun 2018; 9:3502. [PMID: 30158517 PMCID: PMC6115416 DOI: 10.1038/s41467-018-05660-0] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2016] [Accepted: 07/06/2018] [Indexed: 01/08/2023] Open
Abstract
The c-MYC (MYC) oncoprotein is deregulated in over 50% of cancers, yet regulatory mechanisms controlling MYC remain unclear. To this end, we interrogated the MYC interactome using BioID mass spectrometry (MS) and identified PP1 (protein phosphatase 1) and its regulatory subunit PNUTS (protein phosphatase-1 nuclear-targeting subunit) as MYC interactors. We demonstrate that endogenous MYC and PNUTS interact across multiple cell types and that they co-occupy MYC target gene promoters. Inhibiting PP1 by RNAi or pharmacological inhibition results in MYC hyperphosphorylation at multiple serine and threonine residues, leading to a decrease in MYC protein levels due to proteasomal degradation through the canonical SCFFBXW7 pathway. MYC hyperphosphorylation can be rescued specifically with exogenous PP1, but not other phosphatases. Hyperphosphorylated MYC retained interaction with its transcriptional partner MAX, but binding to chromatin is significantly compromised. Our work demonstrates that PP1/PNUTS stabilizes chromatin-bound MYC in proliferating cells. Deregulated MYC activity is oncogenic and is deregulated in a large fraction of human cancers. Here the authors find that protein phosphatase 1 and its regulatory subunit PNUTS controls MYC stability and its interaction with chromatin.
Collapse
Affiliation(s)
- Dharmendra Dingar
- Princess Margaret Cancer Centre, University Health Network, Toronto, M5G 1L7, ON, Canada
| | - William B Tu
- Princess Margaret Cancer Centre, University Health Network, Toronto, M5G 1L7, ON, Canada.,Department of Medical Biophysics, University of Toronto, Toronto, M5G 1L7, Canada
| | - Diana Resetca
- Princess Margaret Cancer Centre, University Health Network, Toronto, M5G 1L7, ON, Canada.,Department of Medical Biophysics, University of Toronto, Toronto, M5G 1L7, Canada
| | - Corey Lourenco
- Princess Margaret Cancer Centre, University Health Network, Toronto, M5G 1L7, ON, Canada.,Department of Medical Biophysics, University of Toronto, Toronto, M5G 1L7, Canada
| | - Aaliya Tamachi
- Princess Margaret Cancer Centre, University Health Network, Toronto, M5G 1L7, ON, Canada
| | - Jason De Melo
- Princess Margaret Cancer Centre, University Health Network, Toronto, M5G 1L7, ON, Canada
| | - Kathleen E Houlahan
- Department of Medical Biophysics, University of Toronto, Toronto, M5G 1L7, Canada.,Ontario Institute for Cancer Research, Toronto, ON Canada M5G 0A3, Canada
| | - Manpreet Kalkat
- Princess Margaret Cancer Centre, University Health Network, Toronto, M5G 1L7, ON, Canada.,Department of Medical Biophysics, University of Toronto, Toronto, M5G 1L7, Canada
| | - Pak-Kei Chan
- Princess Margaret Cancer Centre, University Health Network, Toronto, M5G 1L7, ON, Canada
| | - Paul C Boutros
- Department of Medical Biophysics, University of Toronto, Toronto, M5G 1L7, Canada.,Ontario Institute for Cancer Research, Toronto, ON Canada M5G 0A3, Canada.,Department of Pharmacology and Toxicology, University of Toronto, Toronto, Canada M5S 1A8, Canada
| | - Brian Raught
- Princess Margaret Cancer Centre, University Health Network, Toronto, M5G 1L7, ON, Canada.,Department of Medical Biophysics, University of Toronto, Toronto, M5G 1L7, Canada
| | - Linda Z Penn
- Princess Margaret Cancer Centre, University Health Network, Toronto, M5G 1L7, ON, Canada. .,Department of Medical Biophysics, University of Toronto, Toronto, M5G 1L7, Canada.
| |
Collapse
|
4
|
Nawaito SA, Dingar D, Sahadevan P, Hussein B, Sahmi F, Shi Y, Gillis MA, Gaestel M, Tardif JC, Allen BG. MK5 haplodeficiency attenuates hypertrophy and preserves diastolic function during remodeling induced by chronic pressure overload in the mouse heart. Am J Physiol Heart Circ Physiol 2017; 313:H46-H58. [PMID: 28432058 DOI: 10.1152/ajpheart.00597.2016] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/30/2016] [Revised: 04/03/2017] [Accepted: 04/15/2017] [Indexed: 11/22/2022]
Abstract
MAPK-activated protein kinase-5 (MK5) is a protein serine/threonine kinase that is activated by p38 MAPK and the atypical MAPKs ERK3 and ERK4. The physiological function(s) of MK5 remains unknown. Here, we examined the effect of MK5 haplodeficiency on cardiac function and myocardial remodeling. At 12 wk of age, MK5 haplodeficient mice (MK5+/-) were smaller than age-matched wild-type littermates (MK5+/+), with similar diastolic function but reduced systolic function. Transverse aortic constriction (TAC) was used to induce chronic pressure overload in 12-wk-old male MK5+/- and MK5+/+ mice. Two weeks post-TAC, heart weight-to-tibia length ratios were similarly increased in MK5+/- and MK5+/+ hearts, as was the abundance of B-type natriuretic peptide and β-myosin heavy chain mRNA. Left ventricular ejection fraction was reduced in both MK5+/+ and MK5+/- mice, whereas regional peak systolic tissue velocities were reduced and isovolumetric relaxation time was prolonged in MK5+/+ hearts but not in MK5+/- hearts. The TAC-induced increase in collagen type 1-α1 mRNA observed in MK5+/+ hearts was markedly attenuated in MK5+/- hearts. Eight weeks post-TAC, systolic function was equally impaired in MK5+/+ and MK5+/- mice. In contrast, the increase in E wave deceleration rate and progression of hypertrophy observed in TAC MK5+/+ mice were attenuated in TAC MK5+/- mice. MK5 immunoreactivity was detected in adult fibroblasts but not in myocytes. MK5+/+, MK5+/-, and MK5-/- fibroblasts all expressed α-smooth muscle actin in culture. Hence, reduced MK5 expression in cardiac fibroblasts was associated with the attenuation of both hypertrophy and development of a restrictive filling pattern during myocardial remodeling in response to chronic pressure overload.NEW & NOTEWORTHY MAPK-activated protein kinase-5 (MK5)/p38-regulated/activated protein kinase is a protein serine/threonine kinase activated by p38 MAPK and/or the atypical MAPKs ERK3 and ERK4. MK5 immunoreactivity was detected in adult ventricular fibroblasts but not in myocytes. MK5 haplodeficiency attenuated the progression of hypertrophy, reduced collagen type 1 mRNA, and protected diastolic function in response to chronic pressure overload.
Collapse
Affiliation(s)
- Sherin Ali Nawaito
- Montreal Heart Institute, Montréal, Québec, Canada.,Department of Physiology and Pharmacology, Université de Montréal, Montréal, Québec, Canada
| | - Dharmendra Dingar
- Montreal Heart Institute, Montréal, Québec, Canada.,Department of Biochemistry and Molecular Medicine, Université de Montréal, Montréal, Québec, Canada
| | - Pramod Sahadevan
- Montreal Heart Institute, Montréal, Québec, Canada.,Department of Biochemistry and Molecular Medicine, Université de Montréal, Montréal, Québec, Canada
| | | | - Fatiha Sahmi
- Montreal Heart Institute, Montréal, Québec, Canada
| | - Yanfen Shi
- Montreal Heart Institute, Montréal, Québec, Canada
| | | | - Matthias Gaestel
- Institute of Biochemistry, Hannover Medical School, Hannover, Germany; and
| | - Jean-Claude Tardif
- Montreal Heart Institute, Montréal, Québec, Canada.,Department of Medicine, Université de Montréal, Montréal, Québec, Canada
| | - Bruce G Allen
- Montreal Heart Institute, Montréal, Québec, Canada; .,Department of Physiology and Pharmacology, Université de Montréal, Montréal, Québec, Canada.,Department of Biochemistry and Molecular Medicine, Université de Montréal, Montréal, Québec, Canada.,Department of Medicine, Université de Montréal, Montréal, Québec, Canada
| |
Collapse
|
5
|
Sayyid RK, Dingar D, Fleshner K, Thorburn T, Diamond J, Yao E, Hersey K, Chadwick K, Perlis N, Klotz L, Finelli A, Hamilton R, Kulkarni G, Zlotta A, Fleshner N. What false-negative rates of non-invasive testing are active surveillance patients and uro-oncologists willing to accept in order to avoid prostate biopsy? Can Urol Assoc J 2017; 11:118-122. [PMID: 28458749 DOI: 10.5489/cuaj.4182] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
INTRODUCTION Repeat prostate biopsies in active surveillance patients are associated with significant complications. Novel imaging and blood/urine-based non-invasive tests are being developed to better predict disease grade and volume progression. We conducted a theoretical study to determine what test performance characteristics and costs would a non-invasive test(s) require in order for patients and their physicians to comfortably avoid biopsy. METHODS Surveys were administered to two populations to determine an acceptable false-negative rate and cost for such test(s). Active surveillance patients were recruited at time of followup in clinic at Princess Margaret Cancer Centre. Physician members of the Society of Urological Oncology were targeted via an online survey. Participants were questioned about their demographics and other characteristics that might influence chosen error rates and cost. RESULTS 136 patients and 670 physicians were surveyed, with 130 (95.6%) and 104 (15.5%) responses obtained, respectively. A vast majority of patients (90.6%) were comfortable with a non-invasive test(s) in place of biopsy, with 64.8% accepting a false-negative rate of 5-20%. Most physicians (93.3%) were comfortable with a non-invasive test, with 77.9% accepting a rate of 5-20%. Most patients and physicians felt that a cost of less than $1000 per administration would be reasonable. CONCLUSIONS Most patients/physicians are comfortable with a non-invasive test(s). Although a 5% error rate seems acceptable to many, a substantial subset feels that 99% or higher negative predictive value is required. Thus, a personalized approach with shared decision-making between patients and physicians is essential to optimize patient care in such situations.
Collapse
Affiliation(s)
| | - Dharmendra Dingar
- University Health Network, University of Toronto, Toronto, ON, Canada
| | | | | | | | - Erik Yao
- University Health Network, University of Toronto, Toronto, ON, Canada
| | - Karen Hersey
- University Health Network, University of Toronto, Toronto, ON, Canada
| | - Karen Chadwick
- University Health Network, University of Toronto, Toronto, ON, Canada
| | - Nathan Perlis
- University Health Network, University of Toronto, Toronto, ON, Canada
| | | | - Antonio Finelli
- University Health Network, University of Toronto, Toronto, ON, Canada
| | - Robert Hamilton
- University Health Network, University of Toronto, Toronto, ON, Canada
| | - Girish Kulkarni
- University Health Network, University of Toronto, Toronto, ON, Canada
| | - Alexandre Zlotta
- University Health Network, University of Toronto, Toronto, ON, Canada
| | - Neil Fleshner
- University Health Network, University of Toronto, Toronto, ON, Canada
| |
Collapse
|
6
|
Sayyid R, Dingar D, Fleshner K, Thorburn T, Diamond J, Yao E, Hersey K, Chadwick K, Perlis N, Klotz L, Finelli A, Zlotta A, Hamilton R, Kulkarni G, Fleshner N. MP77-18 WHAT FALSE NEGATIVE RATE OF NON-INVASIVE TESTING ARE ACTIVE SURVEILLANCE PATIENTS AND URO-ONCOLOGISTS WILLING TO ACCEPT IN ORDER TO AVOID PROSTATE BIOPSY? J Urol 2017. [DOI: 10.1016/j.juro.2017.02.2126] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
7
|
Lourenco C, Wasylishen A, Chan-Seng-Yue M, Bros C, Dingar D, Tu W, Kalkat M, Chan PK, Mullen P, Raught B, Boutros P, Penn L. Abstract A10: The myc post-translational landscape: How novel gain-of-function mutants are revealing new stability and functional regulatory systems. Mol Cancer Res 2015. [DOI: 10.1158/1557-3125.myc15-a10] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
The c-MYC (MYC) oncogene plays an important role in tumorigenesis and is implicated in >50% of all human cancers. Deregulation of MYC can occur through abnormally high expression levels, but also through oncogenic lesions in upstream signaling cascades. The study of these signaling pathways have provided an alternative approach for the development of MYC-targeted therapeutics. For example, the study of post-translational modifications (PTMs) of MYC, such as P-T58 and the T58A gain-of-function mutant, identified FBXW7 as a tumor suppressor and the deubiquitinating enzyme USP28 as a therapeutic target.
We considered that MYC is highly modified post-translationally and that unknown mechanistic pathways may be modifying residues, in addition to T58, in order to control MYC stability and/or function. These undiscovered pathways may therefore provide additional opportunities for the development of MYC-targeted therapeutics. These considerations led to recent work in the Penn lab that uncovered clusters of negatively regulating residues of MYC function. These residues include S71/S81, a cluster of residues referred to as MYC-4 (T343, S344, S347 and S348) and a cluster of 6 lysine residues (6K) at the C-terminal end of MYC (K298, K317, K323, K326, K341 and K355). These negatively regulating residues were characterized using alanine (S71/S81 and 340 cluster) and arginine (C-terminal lysines) substitution mutants in our established transformation assays. The S71/S81A and MYC-4A mutants scored with having gain-of-function activity in comparison to wild-type MYC in multiple transformation assays including growth in soft agar and the disruption of regular acini formation using a normal, immortalized MCF10A cell line. In addition, these mutants were shown to regulate additional genes compared to wild-type MYC using genome-wide mRNA expression analysis of MCF10A acini, suggesting that these MYC proteins have gained additional transcriptional targets. Additionally, substitution of the C-terminal lysine residues with arginine (6KR) also revealed gain-of-function activity. 6KR expressing MCF10A and SH-EP cells had increased anchorage-independent growth compared to cells expressing wild-type MYC and was also more potent in promoting xenograft tumor growth of Rat1A and SH-EP cells. Interestingly, all three mutants do not have extended half-lives as seen with T58A, suggesting that functional activity and not stability is contributing to these transformative phenotypes.
The above mutants reveal that each of S71/S81, MYC-4 and C-terminal 6K residues are critically important for the negative regulation of MYC-induced transformation. To further explore these regions of MYC, we used mass spectrometry to identify post-translational modifications that occurred on MYC in growing cells. These data confirm phosphorylation events on S71/81 as well as at MYC-4A. Strikingly, three modifications were directly observed on three of the six lysine residues; acetylation of lysine 323, ubiquitylation of lysine 355 and SUMOylation of lysine 326. The importance of these modifications and the roles that these modifications have in regulating MYC activity are currently under investigation using our established transformation assays. I now aim to understand the contribution of single or multiple modifications within the indicated clusters and how these modifications modulate MYC activity.
Citation Format: Corey Lourenco, Amanda Wasylishen, Michelle Chan-Seng-Yue, Christina Bros, Dharmendra Dingar, William Tu, Manpreet Kalkat, Pak-Kei Chan, Peter Mullen, Brian Raught, Paul Boutros, Linda Penn. The myc post-translational landscape: How novel gain-of-function mutants are revealing new stability and functional regulatory systems. [abstract]. In: Proceedings of the AACR Special Conference on Myc: From Biology to Therapy; Jan 7-10, 2015; La Jolla, CA. Philadelphia (PA): AACR; Mol Cancer Res 2015;13(10 Suppl):Abstract nr A10.
Collapse
Affiliation(s)
| | | | | | | | | | - William Tu
- 1Princess Margaret Cancer Centre, Toronto, ON, Canada,
| | | | - Pak-Kei Chan
- 1Princess Margaret Cancer Centre, Toronto, ON, Canada,
| | - Peter Mullen
- 1Princess Margaret Cancer Centre, Toronto, ON, Canada,
| | - Brian Raught
- 1Princess Margaret Cancer Centre, Toronto, ON, Canada,
| | - Paul Boutros
- 2Ontario Institute for Cancer Research, Toronto, ON, Canada
| | - Linda Penn
- 1Princess Margaret Cancer Centre, Toronto, ON, Canada,
| |
Collapse
|
8
|
Dingar D, Kalkat M, Chan PK, Bailey SD, Srikumar T, Tu WB, Coyaud E, Ponzielli R, Kolyar M, Jurisica I, Huang A, Lupien M, Raught B, Penn LZ. Abstract B04: In vivo BioID identifies novel Myc interacting partners. Mol Cancer Res 2015. [DOI: 10.1158/1557-3125.myc15-b04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Myc oncoprotein is a major driver of cancer initiation and progression, and thus targeting its activity would mark a key therapeutic advance. In a genetic preclinical mouse model, systemic Myc inhibition using the dominant-negative Myc mutant, termed Omomyc, showed that Ras-driven lung cancer could be eradicated without any harmful long-term effects to the animal. However, developing an anti-cancer agent that directly binds and inhibits Myc has not been possible, to date. Therefore, new strategies are required to inhibit Myc in cancer. Understanding the Myc interactome may unravel novel approaches to target Myc in cancer. The BioID proximity-based biotin labeling technique was recently developed for the characterization of protein-protein interaction networks. In BioID, the protein of interest is expressed as a fusion partner biotin ligase (BirA*), which activates biotin. The active biotin reacts with lysine residues on nearby polypeptides. Following a stringent cell lysis and streptavidin-sepharose pulldown, biotinylated proteins can be identified using MS. To date, this method has been applied to a number of different polypeptides expressed in cultured cells. Here we report the adaptation of BioID to the identification of protein-protein interactions surrounding the Myc oncoprotein in human cells grown both under standard culture conditions and in mice as tumor xenografts. Notably, in vivo BioID yielded >100 high confidence Myc interacting proteins, including >30 known binding partners such as MAX (Myc-associated factor X), TRRAP (transformation/transcription domain-associated protein), the enhancer of polycomb homologs 1 and 2 (EPC1, EPC2), lysine acetyltransferase 5 (KAT5). Putative novel Myc interactors include components of the STAGA/KAT5 and SWI/SNF chromatin remodelling complexes (see Penn lab abstract Tu et al), DNA repair and replication factors, general transcription and elongation factors, and transcriptional co-regulators such as the DNA helicase chromodomain 8 (CHD8). Providing additional confidence in these findings, ENCODE ChIP-seq datasets highlight significant coincident binding throughout the genome for the Myc interactors identified here, and we validate the previously unreported CHD8 (an ATP-dependent helicase)-Myc interaction using both a yeast two hybrid analysis and the proximity-based ligation assay (PLA). Additionally, we also validate Myc-BRD4 and Myc-TRIM24 interaction by PLA. In sum, here we identify bona fide interacting partners of Myc in vivo by use of BioID. Our study shows for the first time Myc interactome in vivo, understanding these interactors will shed more light on Myc oncogenesis, which can be used to therapeutically target Myc in cancer.
Citation Format: Dharmendra Dingar, Manpreet Kalkat, Pak-Kei Chan, Swneke D. Bailey, Tharan Srikumar, William B. Tu, Etienne Coyaud, Romina Ponzielli, Max Kolyar, Igor Jurisica, Annie Huang, Mathieu Lupien, Brian Raught, Linda Z. Penn. In vivo BioID identifies novel Myc interacting partners. [abstract]. In: Proceedings of the AACR Special Conference on Myc: From Biology to Therapy; Jan 7-10, 2015; La Jolla, CA. Philadelphia (PA): AACR; Mol Cancer Res 2015;13(10 Suppl):Abstract nr B04.
Collapse
Affiliation(s)
| | | | - Pak-Kei Chan
- 1Princess Margaret Cancer Centre/UHN, Toronto, ON, Canada,
| | | | | | - William B. Tu
- 1Princess Margaret Cancer Centre/UHN, Toronto, ON, Canada,
| | - Etienne Coyaud
- 1Princess Margaret Cancer Centre/UHN, Toronto, ON, Canada,
| | | | - Max Kolyar
- 1Princess Margaret Cancer Centre/UHN, Toronto, ON, Canada,
| | - Igor Jurisica
- 1Princess Margaret Cancer Centre/UHN, Toronto, ON, Canada,
| | - Annie Huang
- 2The Hospital for Sick Children, Toronto, ON, Canada
| | - Mathieu Lupien
- 1Princess Margaret Cancer Centre/UHN, Toronto, ON, Canada,
| | - Brian Raught
- 1Princess Margaret Cancer Centre/UHN, Toronto, ON, Canada,
| | - Linda Z. Penn
- 1Princess Margaret Cancer Centre/UHN, Toronto, ON, Canada,
| |
Collapse
|
9
|
Hickman KA, Lustig LC, Dingar D, Ponzielli R, Bros C, Chan WW, Shin J, Penn LJ. Abstract A24: Characterizing a novel “Minimalist Hybrid Protein” inhibitor designed to target Myc activity in cancer. Mol Cancer Res 2015. [DOI: 10.1158/1557-3125.myc15-a24] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
When deregulated, the c-Myc oncoprotein plays a key role in the development and progression of over 50% of all human cancers. As such, innovative and effective therapeutics are urgently needed to improve the treatment and survival of cancer patients, and we believe that directly modulating the activity of Myc would fill this important gap.
Recent studies using a dominant negative protein, Omomyc, have provided evidence regarding the therapeutic value of inhibiting Myc activity in cancer. Specifically, perturbing Myc activity in vivo eradicates tumors without irreversible damage to normal cells, as demonstrated in mouse models of cancer. Using a similar yet novel strategy, we have generated a minimalist hybrid protein inhibitor known as MaxE47 (ME47), which is composed of the subdomains of different b-HLH-LZ and b-HLH transcription factor families. ME47 is designed to act as a competitive inhibitor of DNA E-box binding by the Myc/Max heterodimer.
We hypothesize that ME47 can be used as a tool to better understand how best to interfere with oncogenic Myc and will lead to the development of Myc-targeted therapeutics. Using our prototype inhibitor, ME47, with Omomyc as a proof-of-concept control, we have established the cell systems and assays necessary to (1) evaluate the anti-cancer efficacy of our Minimalist Hybrid Proteins in human cancer cells, and (2) to determine their mechanism of action and specificity.
Here we have demonstrated that ME47 significantly reduces anchorage-independent growth in soft agar and cell viability in tumor-derived breast cancer cell line MDA-MB-231, but not the non-transformed MCF10A breast cells. ME47 also significantly decreases tumor formation in xenograft mice. To begin to characterize the specificity and mechanism of action of ME47, luciferase reporter and chromatin immunoprecipitation assays were used to evaluate whether ME47 is Myc and/or E-box specific. Using luciferase reporter constructs fused to the promoters of established Myc target genes such as Nucleolin, we have also demonstrated that MaxE47 decreases the ability of Myc to activate target gene transcription.
While this work is focused on the development of a Myc/Max E-box interaction inhibitor, Dr. Linda Penn's research group is also implementing BioID mass spectrometry to identify novel Myc interacting partners (see Penn lab abstract Dingar et al.). This work could potentially reveal new targets for a similar mode of disruptive inhibition, where a Minimalist Hybrid Protein designed to inhibit the association of the novel interacting partner and Myc would disrupt Myc activity.
A direct inhibitor of Myc activity in cancer would re-define the field of Myc therapeutics and could develop into a valuable tool for personalized cancer medicine in those patients with deregulated Myc. The success we have had with our ME47 inhibitor suggests that we are progressing along the path to such an inhibitor, and we look forward to continuing our work with this inhibitor and other Minimalist Hybrid Proteins.
Citation Format: K. Ashley Hickman, Lindsay C. Lustig, Dharmendra Dingar, Romina Ponzielli, Christina Bros, Warren W.C Chan, Jumi Shin, Linda J.Z Penn. Characterizing a novel “Minimalist Hybrid Protein” inhibitor designed to target Myc activity in cancer. [abstract]. In: Proceedings of the AACR Special Conference on Myc: From Biology to Therapy; Jan 7-10, 2015; La Jolla, CA. Philadelphia (PA): AACR; Mol Cancer Res 2015;13(10 Suppl):Abstract nr A24.
Collapse
Affiliation(s)
- K. Ashley Hickman
- 1Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada,
| | - Lindsay C. Lustig
- 1Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada,
| | - Dharmendra Dingar
- 1Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada,
| | - Romina Ponzielli
- 1Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada,
| | - Christina Bros
- 1Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada,
| | - Warren W.C Chan
- 2Institute of Biomaterials & Biomedical Engineering, University of Toronto, Toronto, ON, Canada,
| | - Jumi Shin
- 3University of Toronto, Toronto, ON, Canada
| | - Linda J.Z Penn
- 1Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada,
| |
Collapse
|
10
|
Dingar D, Kalkat M, Chan PK, Srikumar T, Bailey SD, Tu WB, Coyaud E, Ponzielli R, Kolyar M, Jurisica I, Huang A, Lupien M, Penn LZ, Raught B. BioID identifies novel c-MYC interacting partners in cultured cells and xenograft tumors. J Proteomics 2014; 118:95-111. [PMID: 25452129 DOI: 10.1016/j.jprot.2014.09.029] [Citation(s) in RCA: 93] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2014] [Revised: 09/23/2014] [Accepted: 09/28/2014] [Indexed: 10/24/2022]
Abstract
UNLABELLED The BioID proximity-based biotin labeling technique was recently developed for the characterization of protein-protein interaction networks [1]. To date, this method has been applied to a number of different polypeptides expressed in cultured cells. Here we report the adaptation of BioID to the identification of protein-protein interactions surrounding the c-MYC oncoprotein in human cells grown both under standard culture conditions and in mice as tumor xenografts. Notably, in vivo BioID yielded >100 high confidence MYC interacting proteins, including >30 known binding partners. Putative novel MYC interactors include components of the STAGA/KAT5 and SWI/SNF chromatin remodeling complexes, DNA repair and replication factors, general transcription and elongation factors, and transcriptional co-regulators such as the DNA helicase protein chromodomain 8 (CHD8). Providing additional confidence in these findings, ENCODE ChIP-seq datasets highlight significant coincident binding throughout the genome for the MYC interactors identified here, and we validate the previously unreported MYC-CHD8 interaction using both a yeast two hybrid analysis and the proximity-based ligation assay. In sum, we demonstrate that BioID can be utilized to identify bona fide interacting partners for a chromatin-associated protein in vivo. This technique will allow for a much improved understanding of protein-protein interactions in a previously inaccessible biological setting. BIOLOGICAL SIGNIFICANCE The c-MYC (MYC) oncogene is a transcription factor that plays important roles in cancer initiation and progression. MYC expression is deregulated in more than 50% of human cancers, but the role of this protein in normal cell biology and tumor progression is still not well understood, in part because identifying MYC-interacting proteins has been technically challenging: MYC-containing chromatin-associated complexes are difficult to isolate using traditional affinity purification methods, and the MYC protein is exceptionally labile, with a half-life of only ~30 min. Developing a new strategy to gain insight into MYC-containing protein complexes would thus mark a key advance in cancer research. The recently described BioID proximity-based labeling technique represents a promising new complementary approach for the characterization of protein-protein interactions (PPIs) in cultured cells. Here we report that BioID can also be used to characterize protein-protein interactions for a chromatin-associated protein in tumor xenografts, and present a comprehensive, high confidence in vivo MYC interactome. This article is part of a Special Issue entitled: Protein dynamics in health and disease. Guest Editors: Pierre Thibault and Anne-Claude Gingras.
Collapse
Affiliation(s)
- Dharmendra Dingar
- Princess Margaret Cancer Centre, University Health Network, and Department of Medical Biophysics, University of Toronto, Toronto, ON Canada
| | - Manpreet Kalkat
- Princess Margaret Cancer Centre, University Health Network, and Department of Medical Biophysics, University of Toronto, Toronto, ON Canada
| | - Pak-Kei Chan
- Princess Margaret Cancer Centre, University Health Network, and Department of Medical Biophysics, University of Toronto, Toronto, ON Canada
| | - Tharan Srikumar
- Princess Margaret Cancer Centre, University Health Network, and Department of Medical Biophysics, University of Toronto, Toronto, ON Canada
| | - Swneke D Bailey
- Princess Margaret Cancer Centre, University Health Network, and Department of Medical Biophysics, University of Toronto, Toronto, ON Canada
| | - William B Tu
- Princess Margaret Cancer Centre, University Health Network, and Department of Medical Biophysics, University of Toronto, Toronto, ON Canada
| | - Etienne Coyaud
- Princess Margaret Cancer Centre, University Health Network, and Department of Medical Biophysics, University of Toronto, Toronto, ON Canada
| | - Romina Ponzielli
- Princess Margaret Cancer Centre, University Health Network, and Department of Medical Biophysics, University of Toronto, Toronto, ON Canada
| | - Max Kolyar
- Princess Margaret Cancer Centre, University Health Network, and Department of Medical Biophysics, University of Toronto, Toronto, ON Canada
| | - Igor Jurisica
- Princess Margaret Cancer Centre, University Health Network, and Department of Medical Biophysics, University of Toronto, Toronto, ON Canada
| | - Annie Huang
- The Hospital for Sick Children and Department of Paediatrics, University of Toronto, Toronto, ON Canada
| | - Mathieu Lupien
- Princess Margaret Cancer Centre, University Health Network, and Department of Medical Biophysics, University of Toronto, Toronto, ON Canada
| | - Linda Z Penn
- Princess Margaret Cancer Centre, University Health Network, and Department of Medical Biophysics, University of Toronto, Toronto, ON Canada.
| | - Brian Raught
- Princess Margaret Cancer Centre, University Health Network, and Department of Medical Biophysics, University of Toronto, Toronto, ON Canada.
| |
Collapse
|
11
|
Abstract
BioID was performed using FlagBirA⁎ (the R118G biotin ligase mutant protein) and FlagBirA⁎-Myc in HEK293 T-REx cells maintained both under standard cell culture conditions and as mouse xenografts. The mass spectrometry dataset acquired in this study has been uploaded to the MassIVE repository with ID: MSV000078518, and consists of 28 ⁎.raw MS files acquired on an Orbitrap Velos instrument, collected in data-dependent mode. iProphet processed MS/MS search results are also included as a reference. This study has been published as “BioID identifies novel c-MYC interacting partners in cultured cells and xenograft tumors”, by Dingar et al. in the Journal of Proteomics, 2014 [1].
Collapse
|
12
|
Wasylishen AR, Chan-Seng-Yue M, Bros C, Dingar D, Tu WB, Kalkat M, Chan PK, Mullen PJ, Huang L, Meyer N, Raught B, Boutros PC, Penn LZ. MYC phosphorylation at novel regulatory regions suppresses transforming activity. Cancer Res 2013; 73:6504-15. [PMID: 24030976 DOI: 10.1158/0008-5472.can-12-4063] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Despite its central role in human cancer, MYC deregulation is insufficient by itself to transform cells. Because inherent mechanisms of neoplastic control prevent precancerous lesions from becoming fully malignant, identifying transforming alleles of MYC that bypass such controls may provide fundamental insights into tumorigenesis. To date, the only activated allele of MYC known is T58A, the study of which led to identification of the tumor suppressor FBXW7 and its regulator USP28 as a novel therapeutic target. In this study, we screened a panel of MYC phosphorylation mutants for their ability to promote anchorage-independent colony growth of human MCF10A mammary epithelial cells, identifying S71A/S81A and T343A/S344A/S347A/S348A as more potent oncogenic mutants compared with wild-type (WT) MYC. The increased cell-transforming activity of these mutants was confirmed in SH-EP neuroblastoma cells and in three-dimensional MCF10A acini. Mechanistic investigations initiated by a genome-wide mRNA expression analysis of MCF10A acini identified 158 genes regulated by the mutant MYC alleles, compared with only 112 genes regulated by both WT and mutant alleles. Transcriptional gain-of-function was a common feature of the mutant alleles, with many additional genes uniquely dysregulated by individual mutant. Our work identifies novel sites of negative regulation in MYC and thus new sites for its therapeutic attack.
Collapse
Affiliation(s)
- Amanda R Wasylishen
- Authors' Affiliations: Department of Medical Biophysics, University of Toronto; Ontario Cancer Institute, Campbell Family Institute for Cancer Research, Princess Margaret Cancer Centre; and Ontario Institute for Cancer Research, Toronto, Ontario, Canada
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Dingar D, Wasylishen AR, Chan-Seng-Yue M, Huang L, Bros C, Tu W, Meyer N, Boutros PC, Penn LZ. Abstract LB-117: Myc phosphorylation suppresses transformation through novel regulatory regions. Cancer Res 2013. [DOI: 10.1158/1538-7445.am2013-lb-117] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Myc is a proto-oncogenic transcription factor, whose expression is deregulated in numerous human tumours and over-expression in animal models can cause tumorigenesis. Myc is important in cancer initiation and progression and therefore to develop successful approaches targeting Myc, a better understanding of both the mechanisms of Myc regulation and subsequent deregulation in cancer is important. Identification of Myc post-translational modifications (PTMs) that are essential for its oncogenic activity remains largely unknown. Therefore, detecting those key PTMs and there effect on gene expression would shed more light on the mechanisms of Myc dependent tumorigenesis. In our study, we screened a panel of Myc phosphorylation mutants in MCF10A cells for their ability to promote anchorage-independent colony growth and we identified two previously uncharacterized mutants that increased Myc-dependent transformation: S71A/S81A and 340Cl-A (T343A, S344A, S347A, and S348A). We further confirmed that gain-of-function serine and threonine mutants potentiated transformation in SH-EP neuroblastoma cells and three-dimensional MCF10A acini. Additionally, to investigate the mechanism of increased transformation and mutants' selectivity for gene transcription, we conducted genome-wide mRNA expression analysis of MCF10A acini and identified 112 genes regulated by all MYC alleles, and 158 genes regulated by all three transforming phosphorylation mutants but not wild-type MYC. We performed genome-wide ChIP in MCF10A cells, integrated this with gene transcription data, and showed that the majority of genes with altered expression also have MYC binding in their promoter regions, further suggesting that these gene expression changes are directly regulated by Myc. In conclusion, phosphorylation of S71/S81 and 340Cl amino acid residues negatively regulates Myc dependent transformation, suggesting that better understanding of Myc regulation through the phosphorylation of these residues may provide opportunities to therapeutically target Myc.
Citation Format: Dharmendra Dingar, Amanda R. Wasylishen, Michelle Chan-Seng-Yue, Ling Huang, Christina Bros, William Tu, Natalie Meyer, Paul C. Boutros, Linda Z. Penn. Myc phosphorylation suppresses transformation through novel regulatory regions. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr LB-117. doi:10.1158/1538-7445.AM2013-LB-117
Collapse
Affiliation(s)
| | | | | | - Ling Huang
- 1Ontario Cancer Institute/UHN, Toronto, Ontario, Canada
| | | | - William Tu
- 1Ontario Cancer Institute/UHN, Toronto, Ontario, Canada
| | - Natalie Meyer
- 1Ontario Cancer Institute/UHN, Toronto, Ontario, Canada
| | - Paul C. Boutros
- 2Ontario Institute for Cancer Research, Toronto, Ontario, Canada
| | - Linda Z. Penn
- 1Ontario Cancer Institute/UHN, Toronto, Ontario, Canada
| |
Collapse
|
14
|
Dingar D, Konecny F, Zou J, Sun X, von Harsdorf R. Anti-apoptotic function of the E2F transcription factor 4 (E2F4)/p130, a member of retinoblastoma gene family in cardiac myocytes. J Mol Cell Cardiol 2012; 53:820-8. [PMID: 22985930 DOI: 10.1016/j.yjmcc.2012.09.004] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/23/2012] [Revised: 09/05/2012] [Accepted: 09/10/2012] [Indexed: 12/21/2022]
Abstract
The E2F4-p130 transcriptional repressor complex is a cell-cycle inhibitor in mitotic cells. However, the role of E2F4/p130 in differentiated cells is largely unknown. We investigated the role of E2F4/p130 in the regulation of apoptosis in postmitotic cardiomyocytes. Here we demonstrate that E2F4 can inhibit hypoxia-induced cell death in isolated ventricular cardiomyocytes. As analyzed by chromatin immunoprecipitation, the E2F4-p130-repressor directly blocks transcription of essential apoptosis-related genes, E2F1, Apaf-1, and p73α through recruitment of histone deacetylase 1 (HDAC1). In contrast, diminution of the E2F4-p130-HDAC1-repressor and recruitment of E2F1 and histone acetylase activity to these E2F-regulated promoters is required for the execution of cell death. Expression of kinase-dead HDAC1.H141A or HDAC-binding deficient p130ΔHDAC1 abolishes the antiapoptotic effect of E2F4. Moreover, histological examination of E2F4(-/-) hearts revealed a markedly enhanced degree of cardiomyocyte apoptosis. Taken together, our genetic and biochemical data delineate an essential negative function of E2F4 in cardiac myocyte apoptosis.
Collapse
|
15
|
Khairallah M, Dingar D, Khairallah RJ, Vaniotis G, Shi Y, Gaestel M, Stanley WC, Tardif JC, Allen BG. Abstract P188: Suppression of MK2 Signaling Protects Against Pressure Overload-Induced Cardiac Dysfunction. Circ Res 2011. [DOI: 10.1161/res.109.suppl_1.ap188] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
p38 mitogen-activated protein kinases (MAPKs) regulate a broad range of cellular activities but have been implicated in the pathogenesis of cardiovascular diseases. The mechanisms whereby p38 exerts divergent effects are unknown. Current p38 inhibitors both produce serious side effects and loose efficacy with chronic use. Hence, a better understanding of the downstream targets of p38, i.e. MAPK-activated protein kinases (MKs), is essential. We hypothesized that inhibition of MK2 activity (MK2-/-) during chronic pressure overload is cardioprotective. Twelve-week-old MK2-/- and littermate control (MK2+/+) mice were subjected to transverse aortic constriction (2 wks, n=8). MK2-/- mice showed a ∼20% reduced increase in heart weight-to-tibia length ratio (Fig A) despite similar increases in mean blood pressure and ANP expression. Compared to controls, banded MK2-/- hearts also showed preserved left ventricular: (i) fractional shortening, (ii) ejection fraction (preserved at 72.5 ± 2.2% after banding for MK2-/- but decreased from 67.9 ± 3.6% to 58.8 ± 3.4% in MK2+/+, p<0.05, Fig B), and (iii) diastolic function evidenced by the ratio of transmitral and myocardial early diastolic velocities (E/Em preserved after banding in MK2-/- but increased by 78.8 ± 11.1% in MK2+/+, p<0.01). MK2 deficiency did not reduce interstitial fibrosis. For equivalent respiration rates, mitochondria from MK2-/- hearts showed a significant decrease in Ca2+-sensitivity for mitochondrial permeability transition pore opening (p<0.05, Fig C). Overall, these results suggest that MK2 mediates part of the detrimental remodeling evoked by chronic pressure overload-induced activation of p38.
Collapse
Affiliation(s)
| | | | | | | | - Yanfen Shi
- Montreal Heart Institute, Montreal, Canada
| | | | | | | | | |
Collapse
|
16
|
Moïse N, Dingar D, Mamarbachi AM, Villeneuve LR, Farhat N, Gaestel M, Khairallah M, Allen BG. Characterization of a novel MK3 splice variant from murine ventricular myocardium. Cell Signal 2010; 22:1502-12. [PMID: 20570725 PMCID: PMC5300773 DOI: 10.1016/j.cellsig.2010.05.019] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2010] [Revised: 05/14/2010] [Accepted: 05/29/2010] [Indexed: 11/30/2022]
Abstract
p38 MAP kinase (MAPK) isoforms alpha, beta, and gamma, are expressed in the heart. p38alpha appears pro-apoptotic whereas p38beta is pro-hypertrophic. The mechanisms mediating these divergent effects are unknown; hence elucidating the downstream signaling of p38 should further our understanding. Downstream effectors include MAPK-activated protein kinase (MK)-3, which is expressed in many tissues including skeletal muscles and heart. We cloned full-length MK3 (MK3.1, 384 aa) and a novel splice variant (MK3.2, 266 aa) from murine heart. For MK3.2, skipping of exons 8 and 9 resulted in a frame-shift in translation of the first 85 base pairs of exon 10 followed by an in-frame stop codon. Of 3 putative phosphorylation sites for p38 MAPK, only Thr-203 remained functional in MK3.2. In addition, MK3.2 lacked nuclear localization and export signals. Quantitative real-time PCR confirmed the presence of these mRNA species in heart and skeletal muscle; however, the relative abundance of MK3.2 differed. Furthermore, whereas total MK3 mRNA was increased, the relative abundance of MK3.2 mRNA decreased in MK2(-/-) mice. Immunoblotting revealed 2 bands of MK3 immunoreactivity in ventricular lysates. Ectopically expressed MK3.1 localized to the nucleus whereas MK3.2 was distributed throughout the cell; however, whereas MK3.1 translocated to the cytoplasm in response to osmotic stress, MK3.2 was degraded. The p38alpha/beta inhibitor SB203580 prevented the degradation of MK3.2. Furthermore, replacing Thr-203 with alanine prevented the loss of MK3.2 following osmotic stress, as did pretreatment with the proteosome inhibitor MG132. In vitro, GST-MK3.1 was strongly phosphorylated by p38alpha and p38beta, but a poor substrate for p38delta and p38gamma. GST-MK3.2 was poorly phosphorylated by p38alpha and p38beta and not phosphorylated by p38delta and p38gamma. Hence, differential regulation of MKs may, in part, explain diverse downstream effects mediated by p38 signaling.
Collapse
Affiliation(s)
- Nadège Moïse
- Montreal Heart Institute, Université de Montréal, Montreal, Quebec, Canada H3C 3J7
- Department of Biochemistry, Université de Montréal, Montreal, Quebec, Canada H3C 3J7
| | - Dharmendra Dingar
- Montreal Heart Institute, Université de Montréal, Montreal, Quebec, Canada H3C 3J7
- Department of Biochemistry, Université de Montréal, Montreal, Quebec, Canada H3C 3J7
| | - Aida M. Mamarbachi
- Montreal Heart Institute, Université de Montréal, Montreal, Quebec, Canada H3C 3J7
| | - Louis R. Villeneuve
- Montreal Heart Institute, Université de Montréal, Montreal, Quebec, Canada H3C 3J7
| | - Nada Farhat
- Montreal Heart Institute, Université de Montréal, Montreal, Quebec, Canada H3C 3J7
| | - Matthias Gaestel
- Institute of Biochemistry, Hannover Medical School, Carl-Neuberg-Strasse 1, 30625 Hannover, Germany
| | - Maya Khairallah
- Montreal Heart Institute, Université de Montréal, Montreal, Quebec, Canada H3C 3J7
- Department of Biochemistry, Université de Montréal, Montreal, Quebec, Canada H3C 3J7
| | - Bruce G. Allen
- Montreal Heart Institute, Université de Montréal, Montreal, Quebec, Canada H3C 3J7
- Department of Biochemistry, Université de Montréal, Montreal, Quebec, Canada H3C 3J7
- Department of Medicine, Université de Montréal, Montreal, Quebec, Canada H3C 3J7
- Department of Pharmacology and Therapeutics, McGill University, Montréal, Québec, Canada H3G 1Y6
| |
Collapse
|
17
|
Dingar D, Merlen C, Grandy S, Gillis MA, Villeneuve LR, Mamarbachi AM, Fiset C, Allen BG. Effect of pressure overload-induced hypertrophy on the expression and localization of p38 MAP kinase isoforms in the mouse heart. Cell Signal 2010; 22:1634-44. [PMID: 20600854 DOI: 10.1016/j.cellsig.2010.06.002] [Citation(s) in RCA: 43] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2010] [Revised: 06/10/2010] [Accepted: 06/10/2010] [Indexed: 11/28/2022]
Abstract
p38 mitogen-activated protein kinases (MAPKs) are serine/threonine specific protein kinases that respond to cellular stress and regulate a broad range of cellular activities. There are four major isoforms of p38 MAPK: alpha, beta, gamma, and delta. To date, the prominent isoform in heart has been thought to be p38alpha. We examined the expression of each p38 isoform at both the mRNA and protein level in murine heart. mRNA for all four p38 isoforms was detected. p38gamma and p38delta were expressed at protein levels comparable to p38alpha and 38beta, respectively. In the early phase of pressure-overload hypertrophy (1-7 days after constriction of the transverse aorta), the abundance of p38beta, p38gamma and p38delta mRNA increased; however, no corresponding changes were detected at the protein level. Confocal immunofluorescence studies revealed p38alpha and p38gamma in both the cytoplasm and nucleus. In the established phase of hypertrophy induced by chronic pressure overload (7-28 days after constriction of the transverse aorta), p38gamma immunoreactivity accumulated in the nucleus whereas the distribution of p38alpha remained unaffected. Hence, both p38alpha and p38gamma are prominent p38 isoforms in heart and p38gamma may play a role in mediating the changes in gene expression associated with cardiac remodeling during pressure-overload hypertrophy.
Collapse
Affiliation(s)
- Dharmendra Dingar
- Montreal Heart Institute, 5000 Belanger St, Montréal, Québec, Canada
| | | | | | | | | | | | | | | |
Collapse
|
18
|
Dingar D, Benoit MJ, Mamarbachi AM, Villeneuve LR, Gillis MA, Grandy S, Gaestel M, Fiset C, Allen BG. Characterization of the expression and regulation of MK5 in the murine ventricular myocardium. Cell Signal 2010; 22:1063-75. [PMID: 20214976 DOI: 10.1016/j.cellsig.2010.02.009] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2010] [Revised: 02/02/2010] [Accepted: 02/23/2010] [Indexed: 10/19/2022]
Abstract
MK5, a member of the MAPK-activated protein kinase family, is highly expressed in the heart. Whereas MK2 and MK3 are activated by p38 MAPK, MK5 has also been shown to be activated by ERK3 and ERK4. We studied the regulation of MK5 in mouse heart. mRNA for 5 splice variants (MK5.1-5.5), including the original form (MK5.1), was detected. MK5 comprises 14 exons: exon 12 splicing was modified in MK5.2, MK5.3, and MK5.5. MK5.2 and MK5.5 lacked 6 bases at the 3'-end of exon 12, whereas MK5.3 lacked exon 12, resulting in a frame shift and premature termination of translation at codon 3 of exon 13. MK5.4 and MK5.5 lacked exons 2-6, encoding kinase subdomains I-VI, and were kinase-dead. All 5 MK5 variants were detected at the mRNA level in all mouse tissues examined; however, their relative abundance was tissue-specific. Furthermore, the relative abundance of variant mRNA was altered both during hypertrophy and postnatal cardiac development, suggesting that the generation or the stability of MK5 variant mRNAs is subject to regulation. When expressed in HEK293 cells, MK5.1, MK5.2 and MK5.3 were nuclear whereas MK5.4 and MK5.5 were cytoplasmic. A p38 MAPK activator, anisomycin, induced the redistribution of each variant. In contrast, MK5 co-immunoprecipitated ERK3, but not ERK4 or p38 alpha, in control and hypertrophying hearts. GST pull-down assays revealed unbound ERK4 and p38 alpha but no free MK5 or ERK3 in heart lysates. Hence, 1) in heart MK5 complexes with ERK3 and 2) MK5 splice variants may mediate distinct effects thus increasing the functional diversity of ERK3-MK5 signaling.
Collapse
Affiliation(s)
- Dharmendra Dingar
- Montreal Heart Institute, 5000 Belanger St., Montréal, Québec, Canada
| | | | | | | | | | | | | | | | | |
Collapse
|